Novartis (NVS) said Friday that final results from a phase III study supported a slowing decline in kidney function in adults with IgA nephropathy, a progressive autoimmune kidney disease, who were treated with Vanrafia, or atrasentan.

Data showed "clinically meaningful results" with Vanrafia, compared with placebo in estimated glomerular filtration rate change from baseline at the end of study treatment at week 132, the company said.

Novartis said safety was consistent with prior findings.